Traws Pharma receives Nasdaq bid price notice, has until January 25, 2027 to comply
Traws Pharma received a Nasdaq notice on July 29, 2026 that its common stock has traded below $1.00 per share for at least 30 consecutive business days, so it is not currently meeting the minimum bid price requirement. The notice has no immediate effect on the listing, but the company has until January 25, 2027 to regain compliance, and it could face delisting if it does not.
Key points
- Nasdaq notice received July 29, 2026 under Listing Rule 5550(a)(2)
- Closing bid price was below $1.00 for at least 30 consecutive business days
- Compliance period runs until January 25, 2027; regaining compliance requires at least 10 consecutive business days at or above $1.00
- A second 180-day grace period may be available if the company meets listing standards and gives notice of intent to cure
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.